The CDKN2A gene is frequently mutated or deleted in melanoma tumors, leading to a release in the inhibition of cyclin-dependent kinases CDK4 and CDK6, causing a progression from G1 to S-phase and increased cell cycle activity and proliferation (97, 98). This evidence concerns the gene CDK4 and melanoma.